Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT03650491 is registered in ClinicalTrials.gov with Fortis Therapeutics, Inc. as lead sponsor.

NCT NCT03650491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03650491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Fortis Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 3, 2019
Completion date
January 31, 2022
Enrollment
31 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse, multiple myeloma with failed remission